Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
171.8 EUR | -0.06% | +2.60% | +19.22% |
Jun. 11 | Merck KGaA to Build EUR62 Million Facility for Life Science Business | MT |
Jun. 07 | Health Care Up as Defensive Rotation Continues - Health Care Roundup | DJ |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The firm trades with high earnings multiples: 24.99 times its 2024 earnings per share.
- With an enterprise value anticipated at 3.8 times the sales for the current fiscal year, the company turns out to be overvalued.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+19.22% | 80.29B | A | ||
+15.04% | 9.2B | A- | ||
-20.02% | 4.67B | A- | ||
+49.11% | 4.49B | - | ||
+10.17% | 4.27B | B- | ||
+10.55% | 2.25B | B | ||
-25.97% | 2.13B | C- | ||
+16.34% | 2.1B | - | - | |
-40.85% | 1.78B | - | ||
-0.50% | 1.64B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MRK Stock
- Ratings Merck KGaA